430 EAST 29TH STREET, NEW YORK, NY
Completing Asset Acquisition or Sale, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifications to Rights of Security Holders, Change in Company Ownership, Changes in Board, Management or Compensation, Amendments to Articles of Incorporation or Bylaws
Shareholder votes
Other Events
REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS
Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
Amended Annual Report
FY 2023
Q3
Q2
Q1
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Additional Information Statement
Definitive Merger Proxy Statement
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Automatic Shelf Registration Statement
S-8 POS